The active substance, primobolan depot dosage – a polypeptide derived from the lungs of cattle, is a protease inhibitor. It has antiproteoliticheskoe, antifibrinolytic and haemostatic primobolan depot dosage effect. Forming reversible stoichiometric enzyme-inhibiting complex inactivates major protease: trypsin, plasmin, tissue and plasma kallikrein, chymotrypsin, primobolan depot dosage (including activating fibrinolysis). Inhibits both the total proteolytic activity, and the activity of certain proteolytic enzymes.Antiproteaznaya activity determines the effectiveness of primobolan depot dosage primobolan depot dosage in patients with lesions of the pancreas, and other conditions involving high-kallikrein and other proteases in plasma and tissues.It lowers blood fibrinolytic activity, inhibits fibrinolysis and provide haemostatic effect in coagulopathies.Inhibition of kallikrein-kinin system allows the use of a drug for the prevention and treatment of various types of shock.Efficacy is expressed in kallikrein-inactivating units (KIU). 1 corresponds to 140 KIU primobolan depot dosage ng, 100,000 KIU – 14 mg, and 500,000 KIU of primobolan depot dosage -70 mg.
Pharmacokinetics: primobolan depot dosage binds to epithelial cells in the proximal tubules of the kidneys and to a lesser extent – to cartilage as a result of the attraction between molecules of primobolan depot dosage alkaline and acid glycoproteins. The resulting primobolan depot dosage molecule lysosomal activity in the renal tissue break into shorter peptides and amino acids. The half-life of 150 min., Terminal 7-10 hours. Excreted by the kidneys for 5-6 hours in the form of inactive degradation products. If ligation of the renal vessels during pre-clinical trials of primobolan depot dosage concentrations decrease in the blood slows down. Even when administered 1,000,000 KIU dose not detected in urine in an unmodified form.
Indications for use:
Treatment of primary giperfibrinoliticheskogo bleeding: post-traumatic, post-operative (especially during operations on the prostate, lung).
In open heart surgery to reduce bleeding and reduction in blood products needs.
Pancreatitis (acute, exacerbation of chronic), pancreatic necrosis. Diagnostic operations on the pancreas (prevention of enzymatic autolysis of the pancreas during operations on it, and lying next to the abdominal cavity.
Shock (toxic, traumatic, burns, bleeding).
Extensive and deep traumatic tissue damage.
When massive bleeding (during thrombolytic therapy) during extracorporeal circulation.
Prevention of postoperative pulmonary embolism and bleeding; fat embolism in multiple injuries, especially fractures of the lower limbs and the skull bones.
Precautions: during cardiopulmonary surgery by-pass; deep hypothermia; cardiac arrest (increased risk of kidney failure and death); with a history of allergic reaction or the treatment of primobolan depot dosage. DIC (except coagulopathy phase).
Hypersensitivity to primobolan depot dosage. The first and third trimesters of pregnancy, lactation.
Dosing and Administration
Intravenously, slowly, only a position of a patient lying down.
Test dose: at least 10 minutes before administration of the initial dose is administered by intravenous test dose of 1 ml (10 000 KIU primobolan depot dosage) for determining the presence of hypersensitivity to the drug.
For therapeutic purposes: initial dose of 50,000 KIU (a maximum rate of 5 ml / min), and then intravenously at 50,000 KIU / h.
When bleeding and hemorrhages associated with hyperfibrinolysis intravenously 000-200 100 000 KIU, if necessary up to 500 000 KIE (depending on the intensity of bleeding).
During surgical interventions for the prevention, before, during and after the operation: 200 000-400 000 KIU intravenous bolus or slow infusion, and then within the next 2 days 100 000 KIE.
When violations hemostasis in children: 20 000 KIU / kg / day.
Perhaps the topical application of gauze impregnated with 100 000 KIU, applied to the site of bleeding.
In acute pancreatitis: 500 000-1 000 000 KIU, followed by a decrease to 50 000-300 000 KIU for 2-6 days, and the complete abolition of the disappearance of the enzyme toxemia.
During exacerbation of chronic pancreatitis is administered once at the rate of 25,000 KIU within 3-6 days; daily dose: 25 000-50 000 KIU.
Postoperatively and prophylactically (for pancreatic injury hazard) an initial dose of 200,000 KIU then for two days after surgery to 100,000 KIU per 6 hr.
Treatment of primary giperfibrinoliticheskogo bleeding:
Adult initial dose of 500,000 KIU (50 ml), intravenous slow maximum speed which is 5 ml / min, while the patient is in the supine position.
Children: 20 000 KIU / kg / day.
The reduction of bleeding and reduction in blood products needs heart surgery (cardiopulmonary bypass):
2 million KIU should be added to the liquid filling the oxygenator.
During the 2 hour operation the patient receives 5 000 000 KIU primobolan depot dosage.
Special dosage for elderly patients is not required.
Babies: the available data are insufficient dosing.
Data on drug safety for pregnant and breast-feeding is not. In the first and third trimester of pregnancy and is contraindicated during lactation. It is necessary to weigh the benefits and harms of the appointment during pregnancy.
On the part of the central nervous system: psychotic reactions, hallucinations, confusion.
Allergic reactions: urticaria, pruritus, rhinitis, conjunctivitis, bronchospasm, anaphylaxis, anaphylactoid reactions (skin rash, itching, shortness of breath, nausea, increased heart rate up to anaphylactic shock with symptoms of circulatory failure, in some cases with fatal outcome). Repeated administration of the drug may anaphylactic reactions (incidence <0.5%). Even with the second dose tolerability, followed after her introduction of primobolan depot dosage can cause heavy anaphylaxis, which risk increases with repeated doses. In some cases, anaphylactoid reactions observed after the first dose.
In case of hypersensitivity reactions during infundirovaniya, the introduction of the drug should be immediately discontinued if necessary to provide the usual emergency assistance (eg, epinephrine, corticosteroids, fluid replacement).
When surgical operations on the heart and large doses of primobolan depot dosage possible (<1%) a temporary increase in creatinine level, which is very rarely accompanied by symptoms that represent the clinical significance.
Since the cardiovascular system: a higher incidence of myocardial infarction in repeated by-pass operations on the coronary vessels as compared to the control groups, with mortality rates are identical;decrease in blood pressure, tachycardia.
From the digestive system: nausea, vomiting (with the rapid introduction).
Local reactions: thrombophlebitis after repeated puncture and prolonged administration. kob anavar